CA2852127C — Combination drug therapy for the treatment of solid tumors
Assigned to Duke University · Expires 2020-10-27 · 6y expired
What this patent protects
The present invention relates to a pharmaceutical combination that comprises an IGF1R inhibitor and an mTOR inhibitor for the treatment of cancer in a subject; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of medicam…
USPTO Abstract
The present invention relates to a pharmaceutical combination that comprises an IGF1R inhibitor and an mTOR inhibitor for the treatment of cancer in a subject; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of medicament for the treatment of cancer; a kit comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and a method of treating cancer in a subject, especially a human.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.